0000950170-23-071467.txt : 20231219
0000950170-23-071467.hdr.sgml : 20231219
20231219160512
ACCESSION NUMBER: 0000950170-23-071467
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231216
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farquharson Andrew
CENTRAL INDEX KEY: 0001865699
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40672
FILM NUMBER: 231497278
MAIL ADDRESS:
STREET 1: C/O RANI THERAPEUTICS HOLDINGS, INC.
STREET 2: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001856725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
BUSINESS PHONE: (408) 457-3700
MAIL ADDRESS:
STREET 1: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
4
1
ownership.xml
4
X0508
4
2023-12-16
0001856725
Rani Therapeutics Holdings, Inc.
RANI
0001865699
Farquharson Andrew
2051 RINGWOOD AVE
SAN JOSE
CA
95131
true
false
false
false
false
Stock Option (Right to Buy)
4.11
2023-12-16
4
D
false
101276
D
2033-05-24
Class A Common Stock
101276
0
D
Stock Option (Right to Buy)
2.84
2023-12-16
4
A
false
101276
A
2033-05-24
Class A Common Stock
101276
101276
D
The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to
the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's
Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
Svai Sanford. Attorney-in-Fact for Andrew Farquharson
2023-12-19